BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2782 related articles for article (PubMed ID: 776393)

  • 1. Purification of soluble human melanoma-associated antigens.
    Roth JA; Slocum HK; Pellegrino MA; Holmes EC; Reisfeld RA
    Cancer Res; 1976 Jul; 36(7 PT 1):2360-4. PubMed ID: 776393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delayed cutaneous hypersensitivity reactions to melanoma antigen.
    Holmes EC; Roth JA; Morton DL
    Surgery; 1975 Aug; 78(2):160-4. PubMed ID: 1154259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A rapid assay for stimulation of human lymphocytes by tumor-associated antigens.
    Roth JA; Grimm EA; Morton DL
    Cancer Res; 1976 Sep; 36(9 pt.1):3001-10. PubMed ID: 975069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isolation of a soluble tumor-associated antigen from human melanoma.
    Roth JA; Holmes EC; Reisfeld RA; Slocum HK; Morton DL
    Cancer; 1976 Jan; 37(1):104-10. PubMed ID: 1247946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Approaches for the isolation of biologically functional tumor-associated antigens.
    Reisfeld RA; David GS; Ferrone S; Pellegrino MA; Holmes EC
    Cancer Res; 1977 Aug; 37(8 Pt 2):2860-5. PubMed ID: 301432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delayed cutaneous sensitivity reactions to extracts of autologous malignant melanoma: a second look.
    Bluming AZ; Vogel CL; Ziegler JL; Kiryabwire JW
    J Natl Cancer Inst; 1972 Jan; 48(1):17-24. PubMed ID: 4652371
    [No Abstract]   [Full Text] [Related]  

  • 7. Delayed cutaneous hypersensitivity reactions to extracts of breast cancer and melanoma tissue in cancer patients.
    Fossati G; Canevari S; Pierotti MA; Vezzoni P; Porta GD; Vaglini M
    J Natl Cancer Inst; 1979 Jun; 62(6):1381-5. PubMed ID: 286110
    [No Abstract]   [Full Text] [Related]  

  • 8. [Isolation of soluble tumor-associated antigens of human malignant melanoma].
    Suter L
    Fortschr Med; 1978 Aug; 96(32):1615-8. PubMed ID: 680624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Production of melanoma-associated antigen(s) by a defined malignant melanoma cell strain grown in chemically defined medium.
    Chee DO; Boddie AW; Roth JA; Holmes EC; Morton DL
    Cancer Res; 1976 Apr; 36(4):1503-9. PubMed ID: 1260767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Immunotherapy of malignant melanoma (active specific and non-specific immune stimulation) (author's transl)].
    Kokoschka EM; Micksche M
    Wien Klin Wochenschr; 1976 Nov; 88(21):690-6. PubMed ID: 1007279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Melanoma-reactive human cytotoxic T lymphocytes derived from skin biopsies of delayed-type hypersensitivity reactions induced by injection of an autologous melanoma cell line.
    Waanders GA; Rimoldi D; Liénard D; Carrel S; Lejeune F; Dietrich PY; Cerottini JC; Romero P
    Clin Cancer Res; 1997 May; 3(5):685-96. PubMed ID: 9815737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in distribution of human malignant melanoma membrane antigens in the presence of human antibody by immunofluorescence.
    Leong SP; Sutherland CM; Krementz ET
    Cancer Res; 1977 Jan; 37(1):293-8. PubMed ID: 318607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Local adoptive transfer to mice of human delayed hypersensitivity: reactions by the radioisotopic footpad assay.
    Takeichi N; Boone CW; Klein E
    Clin Exp Immunol; 1976 Nov; 26(2):310-3. PubMed ID: 791551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of effect of cyclophosphamide on the immunogenicity of a melanoma antigen vaccine.
    Oratz R; Dugan M; Roses DF; Harris MN; Speyer JL; Hochster H; Weissman J; Henn M; Bystryn JC
    Cancer Res; 1991 Jul; 51(14):3643-7. PubMed ID: 2065322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immediate hypersensitivity skin reactions to human dander in atopic dermatitis. Partial purification and characterization of human dander allergens.
    Yu B; Sawai T; Uehara M; Ishida T; Horiike K; Nozaki M
    Arch Dermatol; 1988 Oct; 124(10):1530-3. PubMed ID: 3421729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective monomorphic and polymorphic HLA class I antigenic determinant loss in surgically removed melanoma lesions.
    Kageshita T; Ishihara T; Campoli M; Ferrone S
    Tissue Antigens; 2005 May; 65(5):419-28. PubMed ID: 15853896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of leukocyte migration by soluble tumor extracts in human malignant melanoma.
    Lapińska M; Jassem J; Kondrat W; Jaśkiewicz J
    Neoplasma; 1980; 27(1):37-42. PubMed ID: 6154899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of bovine cutaneous delayed-type hypersensitivity (DTH) to various test antigens and a mitogen using several adjuvants.
    Hernández A; Yager JA; Wilkie BN; Leslie KE; Mallard BA
    Vet Immunol Immunopathol; 2005 Mar; 104(1-2):45-58. PubMed ID: 15661330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistological analysis of peptide-induced delayed-type hypersensitivity in advanced melanoma patients treated with melanoma antigen-pulsed mature monocyte-derived dendritic cell vaccination.
    Nakai N; Katoh N; Germeraad WT; Kishida T; Ueda E; Takenaka H; Mazda O; Kishimoto S
    J Dermatol Sci; 2009 Jan; 53(1):40-7. PubMed ID: 18804963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preparation and characterization of a polyvalent human melanoma antigen vaccine.
    Bystryn JC; Jacobsen S; Harris M; Roses D; Speyer J; Levin M
    J Biol Response Mod; 1986 Jun; 5(3):211-24. PubMed ID: 3723138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 140.